全球“智能马桶”进入量产阶段，行业由日本 Toto、美国 Kohler 以及多家新创推动，其核心假设依赖明确的行为与健康数据：人类平均每日排便 1.7 次，而便形监测可依据 Bristol 量表识别便秘、炎症、腹泻等趋势。Toto 的 Neorest 机型自 2025 年 8 月上市，起价约 3,200 美元，可供 6 名用户使用，1 分钟内以 LED 与光学传感器检测形状、颜色、硬度与体积，并计划在 2028 年达成年销量 7,300 台。Kohler 的 Dekoda 以 599 美元硬件 + 年费 70 美元（单人）或 130 美元（五人）提供水分、肠道健康与潜血分析，进一步将检测普及化。

技术与监管环境形成另一组数值结构：1970 年代即存在相关光谱技术，但因“禁忌 + 成本”而长期未普及。近期研究推动包括 Kanaria Health 的“排泄监测系统”，其原型曾含“肛纹识别”，后因隐私风险取消。公司已获约 50 万美元（主要来自韩国政府）并申请新加坡 800 万美元研发金；美国 Toi Labs 获得 1,350 万美元（含 NIH 与 AARP 支持），重点用于医院与老人机构。智能马桶意图锁定两大市场：慢性肠胃病患者（如 IBS，从初发症状到首次就诊平均延迟约 3 年，女性患病比例约为男性 2:1），以及日常健康追踪用户。前者的价值主张最为明确。

隐私与行为风控构成产品扩张的关键风险与潜在价值：分析尿液与粪便可推断排卵、肾结石、药物与酒精摄入，也因此需应对法律与数据安全担忧，美国 Roe v. Wade 逆转后部分女性已删除经期 App 作为先例。行为数据亦存在监护价值：高龄者若因失忆减少如厕频率可触发提醒；如厕超过 10 分钟会升高痔疮、盆底功能下降与便秘风险。对多数健康人而言，每日追踪可能“信息过度”，但按周或按月建立基线并关联饮食（脂肪、纤维、蛋白、水分）与运动模式，可构成肠道健康数据库，成为消费健康与医疗交叉的新统计资源。

Global “smart toilet” development is advancing into commercialization, driven by firms such as Japan’s Toto, the US-based Kohler, and multiple startups. Behavioral and biomedical metrics underpin the value proposition: humans defecate an average of 1.7 times per day, and stool-form analysis via the Bristol Scale enables detection of constipation, inflammation and diarrhea trends. Toto’s Neorest model, launched in August 2025 at roughly $3,200, supports six users, employs LED and optical sensors to analyze shape, color, hardness and volume in under one minute, and targets annual sales of 7,300 units by 2028. Kohler’s Dekoda offers a $599 sensor plus annual fees of $70 (single) or $130 (up to five users), providing hydration, gut-health and blood-trace analysis.

Technical and regulatory conditions shape adoption: although spectroscopy-based toilet sensors existed since the 1970s, taboo and cost inhibited uptake. Current innovation includes Kanaria Health’s excreta-analysis system, whose prototype used “anal-print recognition” before being dropped over privacy concerns. The firm has raised roughly $500,000 (mainly from South Korea) and applied for $8 million in Singapore funding; US-based Toi Labs has secured $13.5 million (NIH and AARP included) for elder-care deployment. Two markets dominate demand: chronic gastrointestinal patients — e.g., IBS sufferers, who delay care an average of about three years and exhibit a 2:1 female-to-male ratio — and everyday wellness users, though daily data scrutiny risks overmonitoring.

Privacy and behavioral regulation present both obstacles and potential value. Urine–stool analytics can infer ovulation, kidney stones, alcohol or drug intake, raising exposure to legal and data-security risks, exemplified by US period-tracker deletions after Roe’s rollback. Behavioral data also enable monitoring: reduced toilet frequency may flag elder malnutrition; prolonged sitting beyond 10 minutes raises risks of hemorrhoids, pelvic-floor weakening and constipation. For most healthy users, daily review is excessive, but weekly or monthly baselines tied to diet (fat, fiber, protein, water) and exercise could build a clinically useful gut-health dataset, forming a new statistical resource at the intersection of consumer wellness and medical care.